RxDoctor Payments Data

Joseph Lendvay, PA

Physician Assistant · Loysville, PANPI 1720027840

Payments from drug & device makers

$10,902in general payments, 2019–2025

Across 671 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • GSK$938
  • Boehringer Ingelheim$932
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$572
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$10,902100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,902 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$41,959
Medicare patients
139
Services billed
641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$50,400
EliquisApixaban48$33,147
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$16,767
JanuviaSitagliptin Phosphate14$16,490
RybelsusSemaglutide14$13,222
Xigduo XrDapaglifloz Propaned/Metformin15$11,802
Incruse ElliptaUmeclidinium Bromide19$6,614
InvokanaCanagliflozin12$6,565
Janumet XrSitagliptin Phos/Metformin Hcl12$6,285
TradjentaLinagliptin11$5,405
Rosuvastatin Calcium274$4,109
Atorvastatin Calcium281$3,470
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,040
Lisinopril224$1,942
Montelukast Sodium197$1,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$932$55,80564 claims
PfizerEliquis$187$33,14748 claims
GSKTrelegy Ellipta, Incruse Ellipta$938$23,38139 claims
MerckJanuvia, Janumet Xr$350$22,77426 claims
Novo NordiskRybelsus$1,795$13,22214 claims
Johnson & JohnsonInvokana$121$6,56512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Loysville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →